A phase III randomized, open label study to evaluate the efficacy and safety of Petosemtamab plus Pembrolizumab vs. Pembrolizumab in head and neck squamous cell carcinoma in the first line treatment of PD-L1+ (CPS 1) metastatic/recurrent disease without curative therapy available